Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients-Reference-Cited by-同舟云学术

Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients

Published:2017-07-14 Issue:10 Volume:49 Page:1867-1873
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Donderski Rafał,Stróżecki Paweł,Sulikowska Beata,Grajewska Magdalena,Miśkowiec Ilona,Stefańska Anna,Siódmiak Joanna,Odrowąż-Sypniewska Grażyna,Manitius Jacek

Funder

¨NERKADAR¨ foundation in Department of Nephrology, Hypertension and Internal Medicine in Bydgoszcz, Poland

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/article/10.1007/s11255-017-1655-2/fulltext.html

Reference20 articles.

1. Bomback AS (2016) Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety. Blood Purif 41(1–3):166–170. doi: 10.1159/000441262

2. Pitt B (2004) Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217(1–2):53–58 (Review)

3. Chhokar VS, Sun Y, Bhattacharya SK (2005) Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111:871–878